CN112773798B - 作为d-氨基酸氧化酶抑制剂的已知化合物的用途 - Google Patents

作为d-氨基酸氧化酶抑制剂的已知化合物的用途 Download PDF

Info

Publication number
CN112773798B
CN112773798B CN202011486413.7A CN202011486413A CN112773798B CN 112773798 B CN112773798 B CN 112773798B CN 202011486413 A CN202011486413 A CN 202011486413A CN 112773798 B CN112773798 B CN 112773798B
Authority
CN
China
Prior art keywords
schizophrenia
daao
disease
drugs
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011486413.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112773798A (zh
Inventor
宇凤·简·曾
刘玉丽
孙仲铭
胡海国
刘智民
赖文崧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Yang Ming Chiao Tung University
Original Assignee
National Yang Ming Chiao Tung University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Yang Ming Chiao Tung University filed Critical National Yang Ming Chiao Tung University
Priority to CN202011486413.7A priority Critical patent/CN112773798B/zh
Publication of CN112773798A publication Critical patent/CN112773798A/zh
Application granted granted Critical
Publication of CN112773798B publication Critical patent/CN112773798B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G01N2333/90644—D-Amino acid oxidase (1.4.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Library & Information Science (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
CN202011486413.7A 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途 Active CN112773798B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011486413.7A CN112773798B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461986480P 2014-04-30 2014-04-30
US61/986,480 2014-04-30
PCT/US2015/028385 WO2015168346A1 (en) 2014-04-30 2015-04-30 Use of known compounds as d-amino acid oxidase inhibitors
CN202011486413.7A CN112773798B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
CN201580021632.9A CN106687626B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580021632.9A Division CN106687626B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途

Publications (2)

Publication Number Publication Date
CN112773798A CN112773798A (zh) 2021-05-11
CN112773798B true CN112773798B (zh) 2024-03-29

Family

ID=54359315

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011486413.7A Active CN112773798B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
CN201580021632.9A Active CN106687626B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580021632.9A Active CN106687626B (zh) 2014-04-30 2015-04-30 作为d-氨基酸氧化酶抑制剂的已知化合物的用途

Country Status (15)

Country Link
US (2) USRE49340E1 (cg-RX-API-DMAC10.html)
EP (2) EP3498275B1 (cg-RX-API-DMAC10.html)
JP (2) JP2017524143A (cg-RX-API-DMAC10.html)
KR (2) KR20160147868A (cg-RX-API-DMAC10.html)
CN (2) CN112773798B (cg-RX-API-DMAC10.html)
AU (1) AU2015253099B2 (cg-RX-API-DMAC10.html)
CA (1) CA2946153C (cg-RX-API-DMAC10.html)
DK (1) DK3137658T3 (cg-RX-API-DMAC10.html)
ES (2) ES2951736T3 (cg-RX-API-DMAC10.html)
IL (1) IL248567B (cg-RX-API-DMAC10.html)
MX (2) MX2016011551A (cg-RX-API-DMAC10.html)
PT (1) PT3137658T (cg-RX-API-DMAC10.html)
SG (2) SG10202102125SA (cg-RX-API-DMAC10.html)
TW (1) TWI675660B (cg-RX-API-DMAC10.html)
WO (1) WO2015168346A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202102125SA (en) * 2014-04-30 2021-04-29 Yufeng Tseng Use of known compounds as d-amino acid oxidase inhibitors
EP4289425A3 (en) 2016-09-14 2024-08-07 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CN108143734A (zh) * 2018-02-09 2018-06-12 南京中医药大学 阿莫地喹及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用
US20220016099A1 (en) * 2018-12-06 2022-01-20 Trinuero Benzimidazole or benzoxazole derivatives for preventing and treating central nervous system disease, diabetes, and complications thereof
CA3127607A1 (en) * 2019-01-23 2020-07-30 The Regents Of The University Of Michigan Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
CN110297839B (zh) * 2019-06-25 2022-04-12 中国人民解放军军事科学院军事医学研究院 药物适应症的查询方法、装置、计算机设备和存储介质
MX2026004033A (es) * 2021-06-23 2026-05-04 Yoda Therapeutics Inc Derivados del benzimidazol para el tratamiento y/o la prevencion de enfermedades y trastornos mediados por el nlrp3

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619652A (en) 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
PT93943A (pt) 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9304500D0 (en) 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
ATE455083T1 (de) * 1995-11-13 2010-01-15 Akiko Itai Verfahren zum entwurf einer physiologisch aktiven verbindung
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
WO2003039540A2 (en) 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
WO2005089753A2 (en) 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
ATE425791T1 (de) * 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
US20090306169A1 (en) * 2005-10-06 2009-12-10 Brandish Philip E Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
AU2007249348C1 (en) * 2006-05-10 2013-01-17 Laclede, Inc. Compositions and methods for enzymatic treatment of lung disorders
KR20090024823A (ko) * 2006-06-30 2009-03-09 세프라코 아이엔시. Ｄ-아미노산 옥시다제의 융합된 헤테로사이클 억제제
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US20120149743A9 (en) * 2008-06-02 2012-06-14 Ironwood Pharmaceuticals, Inc Selenophene and Selenazole Carboxylic Acid Derivatives
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
KR101348984B1 (ko) * 2012-01-31 2014-01-10 전남대학교산학협력단 박테리아 시토크롬 ｐ450을 이용한 오메프라졸로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물
SG10202102125SA (en) * 2014-04-30 2021-04-29 Yufeng Tseng Use of known compounds as d-amino acid oxidase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eradication of Helicobacter pylori Infection Improves evodopa Action, Clinical Symptoms and Quality of Life in Patients with Parkinson’s Disease;Hashim等;《PLOS ONE》;第第9卷卷(第第9卷期);第1-7页 *

Also Published As

Publication number Publication date
NZ723652A (en) 2021-04-30
US9868975B2 (en) 2018-01-16
EP3137658B1 (en) 2022-03-30
EP3498275C0 (en) 2023-06-07
CN112773798A (zh) 2021-05-11
AU2015253099B2 (en) 2019-07-18
IL248567B (en) 2022-08-01
MX2016011551A (es) 2017-02-28
SG10202102125SA (en) 2021-04-29
USRE49340E1 (en) 2022-12-20
TW201610246A (zh) 2016-03-16
PT3137658T (pt) 2022-05-05
JP6941326B2 (ja) 2021-09-29
EP3137658A4 (en) 2018-03-14
JP2020112558A (ja) 2020-07-27
AU2015253099A1 (en) 2016-09-15
CN106687626B (zh) 2021-01-26
SG11201607166XA (en) 2016-09-29
CA2946153C (en) 2022-06-14
ES2951736T3 (es) 2023-10-24
KR20220123738A (ko) 2022-09-08
US20170037448A1 (en) 2017-02-09
KR102537686B1 (ko) 2023-05-30
WO2015168346A1 (en) 2015-11-05
EP3498275B1 (en) 2023-06-07
KR20160147868A (ko) 2016-12-23
MX2021000133A (es) 2021-03-25
DK3137658T3 (da) 2022-05-02
JP2017524143A (ja) 2017-08-24
IL248567A0 (en) 2016-12-29
CA2946153A1 (en) 2015-11-05
CN106687626A (zh) 2017-05-17
ES2911879T3 (es) 2022-05-23
EP3498275A1 (en) 2019-06-19
EP3137658A1 (en) 2017-03-08
TWI675660B (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
JP6941326B2 (ja) 疾患をｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害により治療するための医薬組成物
Maksymetz et al. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Cid et al. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl [1, 2, 4] triazolo [4, 3-a] pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor
US9085562B2 (en) 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
US20130225623A1 (en) Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
CA2850707A1 (en) Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2011053636A1 (en) Methods of treating psychiatric or neurological disorders with mglur antagonists
HK1233313B (en) Use of known compounds as d-amino acid oxidase inhibitors
HK40042967B (en) Use of known compounds as d-amino acid oxidase inhibitors
US20170305913A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
HK40042967A (en) Use of known compounds as d-amino acid oxidase inhibitors
WO2019068771A1 (en) USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS
HK1233313A1 (en) Use of known compounds as d-amino acid oxidase inhibitors
NZ723652B2 (en) Use of known compounds as d-amino acid oxidase inhibitors
Morrow et al. Glutamatergic approaches for the treatment of schizophrenia
EP4561567A2 (en) Inhibitors of pde11a4 and methods of using same
Onyameh Central Nervous System (CNS) Multi-receptor Ligands for Schizophrenia
Ofori Tetrahydroisoquinoline and 1-(pyridin-2-Yl) piperazine as Multi-Receptor Probes for CNS Drug Design
Calcaterra ESTABLISHMENT AND UTILIZATION OF A DRUG DISCOVERY PLATFORM FOR KV11. 1-3.1, A NOVEL TARGET FOR THE TREATMENT OF SCHIZOPHRENIA
EA039381B1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042967

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant